General American Investors Co. Inc. Sells 15,000 Shares of Merck & Co., Inc. (NYSE:MRK)

General American Investors Co. Inc. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 5.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 240,191 shares of the company’s stock after selling 15,000 shares during the quarter. Merck & Co., Inc. comprises about 1.4% of General American Investors Co. Inc.’s investment portfolio, making the stock its 23rd largest holding. General American Investors Co. Inc.’s holdings in Merck & Co., Inc. were worth $18,408,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in MRK. Cable Hill Partners LLC boosted its position in Merck & Co., Inc. by 3.7% during the 4th quarter. Cable Hill Partners LLC now owns 11,892 shares of the company’s stock worth $911,000 after buying an additional 419 shares during the period. Doyle Wealth Management increased its stake in shares of Merck & Co., Inc. by 2.7% in the 4th quarter. Doyle Wealth Management now owns 190,494 shares of the company’s stock valued at $14,599,000 after acquiring an additional 4,955 shares in the last quarter. Donoghue Forlines LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $2,297,000. Shapiro Capital Management LLC increased its stake in Merck & Co., Inc. by 28.9% during the 4th quarter. Shapiro Capital Management LLC now owns 1,880,216 shares of the company’s stock valued at $144,100,000 after purchasing an additional 421,118 shares in the last quarter. Finally, Prudential PLC increased its stake in Merck & Co., Inc. by 73.2% during the 4th quarter. Prudential PLC now owns 222,116 shares of the company’s stock valued at $17,023,000 after purchasing an additional 93,890 shares in the last quarter. 72.88% of the stock is currently owned by institutional investors and hedge funds.

MRK has been the topic of a number of analyst reports. SVB Leerink cut their price objective on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Mizuho started coverage on shares of Merck & Co., Inc. in a report on Friday, April 1st. They issued a “buy” rating and a $100.00 price target on the stock. Barclays boosted their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a report on Tuesday, April 12th. Finally, JPMorgan Chase & Co. cut their price target on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a report on Friday, January 28th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $90.69.

NYSE:MRK traded up $0.68 on Tuesday, hitting $93.00. The stock had a trading volume of 17,265,782 shares, compared to its average volume of 12,255,947. The company has a quick ratio of 1.02, a current ratio of 1.27 and a debt-to-equity ratio of 0.80. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $94.56. The business’s 50-day simple moving average is $84.58 and its two-hundred day simple moving average is $80.77. The stock has a market cap of $235.18 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 1.22 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.31. Merck & Co., Inc. had a return on equity of 49.57% and a net margin of 26.27%. The business had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. During the same quarter in the previous year, the company posted $1.40 EPS. The company’s revenue was up 31.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 7.31 EPS for the current year.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.